Arterial Hypertension and Methylenetetrahydrofolate Reductase C677T Gene Polymorphism

Objective: to determine the association of polymorphisms of C677T methylenetetrahydrofolate reductase (MTHFR) gene with essential arterial hypertension (EH) in the group of patients of Belarusian ethnicity. Methods. The clinical examination and molecular genetic study of the polymorphism C677T of MTHFR gene by polymerase chain reaction and restriction fragment length polymorphism analysis were performed in 423 people, including 315 patients with EH and 108 healthy individuals. Results. The distribution of C and T alleles of polymorphism C677T of the MTHFR gene in hypertensive patients was 67.8 and 32.2 %, in normotensive individuals - 71.8 and 28.2 %, respectively. In the group of hypertensive patients, the prevalence of the TT (C677T) genotype of the MTHFR gene was 10.8 %, in the healthy group - 5.5 %. The TT genotype of the C677T MTHFR gene was more common in hypertensive patients with obesity in comparison with hypertensive patients with body mass index < 29.9 kg /m² (61.8 vs 38.2 %, respectively; p<0.05). Difference of distributions of genotypes (the recessive model) of the C677T polymorphism of the MTHFR gene was observed between patients with early EH development (before 45 years, n=86) and 108 normotensive individuals (n=108) (odds ratio [OR] 2.65, 95 % confidence interval [CI] 1.07-6.55). This difference was more pronounced among men (OR 9.55, 95% CI 1.37-66.53). Conclusions. In this study the mutant TT genotype of C677T polymorphism of the MTHFR gene was associated with EH development in patients under 45 years and predominantly in men.

эссенциальная артериальная гипертензия, ген метилентетрагидрофолатредуктазы, генетический полиморфизм, гомоцистеин, essential arterial hypertension, methylenetetrahydrofolate reductase gene, genetic polymorphism, homocysteine

1. Thomsen L. C., McCarthy N. S., Melton P. E. et al. The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. J. Hypertens 2017;35 (l):13-139. DOI: 10.1097/HJH. 0000000000001131.

2. Tan A. G., Kifley A., Mitchell P. et al. Associations Between Methylenetetrahydrofolate Reductase Polymorphisms, Serum Homocysteine Levels, and Incident Cortical Cataract. JAMA Ophthalmol 2016;134 (5):522-528.

3. Wu Y. L., Ding X. X., Sun Y. H. et al. Methylenetetrahydrofolate reductase (MTHFr) C677T/A1298C polymorphisms and susceptibility to Parkinson's disease: a meta-analysis. J. Neurol Sci 2013;335 (1-2):14-21.

4. Nathalie M.J. van der Put, Fons Gabreels et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J. Hum Genet 1998;62 (5):1044-1051.

5. Klerk M., Verhoef P., Clarke R. et al. MTHFR Studies Collaboration Group. MTHFR 677C®T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288 (16):2023-2031.

6. Brattström L., Wilcken D. E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98 (23):2520-2526.

7. Мрочек А. Г., Нечесова Т. А., Коробко И. Ю. и др. Диагностика, лечение и профилактика артериальной гипертензии. Национальные рекомендации. Минск: Приложение к журналу «Кардиология в Беларуси» 2010; 52 с.

8. Tylicki L., Födinger M., Puttinger H. et al. Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension. Am J. Hypertens 2005;18:1442-1448. DOI: 10.101/j.amjhyper. 2005.05.012.

9. Rodmgïez-Esparragon F., Hernandez-Perera O., Rodriguez- Pèrez J. et al. The effect of methyt enet etrahydroJolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 2003;25:209-220.

10. Benes P., Kankova K., Muzik J. et al. Methylenetetrahydrofolate reductase polymorphism, type II diabetes mellitus, coronary artery disease, and essential hypertension in the Czech population. Mol Genet Metab 2001;73:188-195.

11. Hui P., Nakayama T., Morita A. et al. Common single nucleotide polymorphisms in Japanese patients with essential hypertension: aldehyde dehydrogenase 2 gene as a risk factor independent of alcohol consumption. Hypertens Res 2007;30:585-591.

12. Lwin H., Yokoyama T., Yoshiike N. et al. Polymorphism of methylenetetrahydrofolate reductase gene (C677T MTHFR) is not a confounding factor of the relationship between serum uric acid level and the prevalence of hypertension in Japanese men. Circ J. 2006;70:83-87.

13. Xing X., Hua Q. Relationships between the polymorphism of methylenetetrahydrofolate reductase gene C677T and hypertension, cardiac structure and function. Med J. Chin PLA 2007;32:741-744.

14. Luo J. W., Tang Y., Chen H. et al. Study on MTHFR C677T polymorphism in hypertensive subjects with blood stasis syndrome. J. Beijing Univ Tradit Chin Med 2008;31:351-354.

15. Tang Y., Chen H., Wu X. Y., Luo J. W. The C677T point mutation of N5,10-methylenetetrahydrofolate reductase (MTHFR) and essential hypertension. Mol Cardiol China 2007;7:205-207.

16. Yang K. M., Jia J., Mao L. N. et al. Methylenet etrahydrofolate reductase C677T gene polymorphism and essential hypertension: A meta-analysis of 10,415 subjects. Biomed Rep 2014;2 (5):699-708.

17. Ghogomu S. M., Ngolle N. E., Mouliom R. N., Asa B. F. Association between the MTHFR C677T gene polymorphism and essential hypertension in South West Cameroon. Genet Mol Res 2016;15 (1). DOI: 10.4238/gmr. 15017462.

18. Nassereddine S., Kassogue Y., Korchi F. et al. Association of methylenetetrahydrofolate reductase gene (C677T) with the risk of hypertension in Morocco. BMC Res Notes 2015;8:775. DOI: 10.1186/s13104-015-1772-x.

19. Amit Kumar, Pradeep Kumar, Manya Prasad et al. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene (MTHFR gene) with ischemic stroke: a meta-analysis. J. Neurol Res 2015;37 (7):568-577.

20. Jiang S., Li J., Zhang Y. et al. Methylenetetrahydrofolate reductase C677T polymorphism, hypertension and risk of stroke: a prospective, nested case-control study. Int J. Neurosci 2017;127 (3):253-260.

21. Xu B., Kong X., Xu R. et al. Homocysteine and all-cause mortality in hypertensive adults without pre-existing cardiovascular conditions: Effect modification by MTHFR C677T polymorphism. Medicine (Baltimore) 2017;96 (8):e5862. DOI: 10.1097/MD. 0000000000005862.

22. Tang Z., Xiao L., Wang J. Q., Zhang T. Analysis of metabolism-related indicators and MTHFR gene polymorphism in patients with H-type hypertension. Minerva Med 2017;108 (2):103-107. DOI: 10.23736/S0026-4806.16.04951-X.

23. Qing Zhang, De-Xing Qiu, Rong-Li Fu et al. H-Type Hypertension and C. Reactive Protein in Recurrence of Ischemic Stroke. Int J. Environ Res Public Health 2016;13 (5), 477:1-9.

24. Mi G. Q., Fu Y., Mao J.J., Xu M. Z. Relationship between “H type" hypertension and senile recurrent cerebral infarction. Chin J. Gerontol 2011;31:1859-1860.

25. Wang H. L., Tan S., Song B. et al. Correlation of H-type hypertension and prognosis of ischemic stroke. Zhonghua Yi Xue Za Zhi 2012;92 (17):1183-1186.

26. Graham I. M., Daly L. E., Refsum H. M. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J. Am Med Assoc 1997;277:1775-1781.

27. Hu Z. 1., Hou Q. Z., Zhao S. et al. Structural and functional changes of the carotid artery and their relationship with subclinical inflammation in patients with H-type hypertension. Nan Fang Yi Ke Da XueXue Bao 2012;32 (8):1175-1178.

28. Chen Z., Wang F., Zheng Y. et al. H-type hypertension is an important risk factor of carotid atherosclerotic plaques. Clin Exp Hypertens 2016;38 (5):424-428. DOI: 10.3109/10641963.2015. 1116547.

29. Pang H., Han B., Fu Q., Zong Z. Association of High Homocysteine Levels With the Risk Stratification in Hypertensive Patients at Risk of Stroke. Clin Ther 2016;38 (5):1184-92. DOI: 10.1016/ j.clinthera. 2016.03.007.